Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497472 | 0.84 | BAZ2B (0.50) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL23952005 | 0.82 | BAZ2B (0.49) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL9197132 | 0.81 | BAZ2B (0.47) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL261645 | 0.81 | GABRP (0.47) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL4566308 | 0.80 | BAZ2B (0.46) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL4566309 | 0.80 | BAZ2B (0.46) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL19500071 | 0.80 | TTR (0.47) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL27680446 | 0.78 | NPC1 (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL643727 | 0.76 | SMN1; SMN2 (0.43) | ALDH1A1GAALMNAMAPK1 | |
| SCHEMBL28140695 | 0.76 | MEN1 (0.46) | BAZ2BBAZ2AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0434070-B1 | Pyrrolealdehyde derivative | MITSUBISHI CHEM CORP (JP) | 1995-08-09 | — | — | EP | claimed |
| EP-0434070-A2 | Pyrrolealdehyde derivative | Mitsubishi Chemical Corporation (JP) | 1991-06-26 | — | — | EP | claimed |
| CN-122055361-A | Fascin inhibitors | 北京双鹤润创科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720054-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| WO-2025045233-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-3930849-B1 | THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024240245-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2024-11-28 | — | — | WO | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-6066639-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0904271-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997041115-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-11-06 | — | — | WO | disclosed |
| US-RE35096-E | Antilipemic, anticholesterol, arteriosclerosis | MITSUBISHI CHEMICAL CORPORATION (JP) | 1995-11-21 | — | — | US | disclosed |
| EP-0434070-B1 | Pyrrolealdehyde derivative | MITSUBISHI CHEM CORP (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5153217-A | Antiiipemic, anticholesterol agents | MITSUBISHI KASEI CORPORATION (JP) | 1992-10-06 | — | — | US | disclosed |
| US-5082856-A | Hyperlipemia, arteriosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0434070-A2 | Pyrrolealdehyde derivative | Mitsubishi Chemical Corporation (JP) | 1991-06-26 | — | — | EP | disclosed |
| EP-0347902-A2 | Pyrrolecarboxylic acid derivatives | Mitsubishi Chemical Corporation (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | BAZ2B 1391/4885BAZ2A 1632/4885ALDH1A1 3157/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | BAZ2B 1391/4885BAZ2A 1632/4885ALDH1A1 3157/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | BAZ2B 1391/4885BAZ2A 1632/4885ALDH1A1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.